StreetInsider.com News Articles

Chardan Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 20 Oct 2026 06:48:19 -0400

Chardan analyst Gautam Chukka initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $8.00.

The analyst comments "TVRD is a clinical stage biotech developing oral, direct STAT3 inhibitors, led by TTI-109 in ulcerative colitis (UC). STAT3 is where IL-6, IL-23 and other inflammatory signals converge, yet no direct STAT3 drug has been approved and the field is full of failures. Its first drug, TTI-101, missed in IPF as GI side effects drove patients off drug. TTI-109, its prodrug, is built to fix that. Our Buy rests on one condition: Tvardi raising the $35-40M

Chardan Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 20 Oct 2026 06:48:19 -0400

Chardan analyst Gautam Chukka initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $8.00.

Chardan Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 20 Oct 2026 06:48:19 -0400

Chardan analyst Gautam Chukka initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $8.00.

Chardan Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 20 Oct 2026 06:48:19 -0400

Chardan analyst Gautam Chukka initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $8.00.

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

Wed, 14 Oct 2026 08:00:00 -0400

HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.

Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

Wed, 14 Oct 2026 08:00:00 -0400

Members of the Tvardi management team will be available to meet with investors who are registered to attend the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the

Tvardi publishes preclinical STAT3 inhibitor data for ulcerative colitis

Thu, 24 Sep 2026 08:00:20 -0400

Tvardi Therapeutics (NASDAQ: TVRD) announced the publication of preclinical data evaluating its STAT3 inhibitor TTI-101 in the International Journal of Molecular Sciences, adding to existing evidence for STAT3 inhibition as a potential approach to treating ulcerative colitis (UC).

The study, titled "Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy," tested TTI-101 in a mouse model designed to replicate the progression from chronic colitis to colorectal cancer. In that model, TTI-101 accumulated in the colon at approximately eight times higher concentrations than in plasma, normalized STAT3-regulated gene expression, and prevented the formation of colon polyps and adenocarcinomas. Patients with UC are estimated

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

Thu, 24 Sep 2026 08:00:00 -0400

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology

Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi’s next-generation STAT3 inhibitor, in UC

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

Thu, 24 Sep 2026 08:00:00 -0400

Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi’s next-generation STAT3 inhibitor, in UC

Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 08 Sep 2026 06:37:19 -0400

(Updated - September 8, 2026 6:37 AM EDT)

Lucid Capital Markets analyst Elemer Piros initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $14.00.

The analyst comments "The company’s first-generation molecule, TTI-101, provided important early validation of the platform, demonstrating systemic exposure, human tumor target engagement and preliminary antitumor activity. However, the subsequent Phase 2 REVERT IPF study failed to demonstrate meaningful clinical efficacy, materially weakening the original fibrosis thesis. Tvardi has since reset its strategy around TTI-109, a next-generation prodrug of TTI-101, with ulcerative colitis (UC) selected as its lead indication. We view

Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 08 Sep 2026 06:37:19 -0400

(Updated - September 8, 2026 6:37 AM EDT)

Lucid Capital Markets analyst Elemer Piros initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $14.00.

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

H.C. Wainwright Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD)

Mon, 17 Aug 2026 06:50:27 -0400

H.C. Wainwright analyst Sara Nik reiterated a Buy rating and $9.00 price target on Tvardi Therapeutics Inc (NASDAQ: TVRD).

The analyst commented: "Tvardi announced 2Q26 financial results and provided a business update. In our view the quarter reset the company's strategic frame around two assets and one key upcoming event. Key updates include: The company reported topline results from the healthy volunteer study of TTI-109, its next-generation STAT3 inhibitor. Per the company, TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and, across the active dose range, produced reductions in cellular and humoral immune populations that the company notes are known to correlate

Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c

Fri, 14 Aug 2026 07:31:31 -0400

Tvardi Therapeutics (NASDAQ: TVRD) reported Q2 EPS of ($0.69), $0.01 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Tvardi Therapeutics (TVRD) click here.

Form 10-Q Tvardi Therapeutics, For: Jun 30

Fri, 14 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26924491.html

Form 10-Q Tvardi Therapeutics, For: Jun 30

Fri, 14 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26924491.html

Form 8-K Tvardi Therapeutics, For: Aug 14

Fri, 14 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26924473.html

Form 8-K Tvardi Therapeutics, For: Aug 14

Fri, 14 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26924473.html

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET